Gastroesophageal and Colorectal Cancers | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Gastroesophageal and Colorectal Cancers

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics:

• Introduction (0:00)
• The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30)
• The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53)
• First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16)
• The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16)
• Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42)
• Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24)
• The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32)
• Tolerability and Other Practical Considerations with ICIs (1:25:57)
• The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14)
• The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36)

NCPD information and select publications